### IAP20 Acs

# CECLULATED 30 JAN 2006

#### IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/EP2004/007737

International Filing Date : July 13, 2004

Priority Date(s) Claimed : July 28, 2003

Applicant(s) (DO/EO/US) : Thorsten BLUME et al.

Title: THIOMORPHOLINO STEROID COMPOUNDS, THE USE THEREOF FOR THE PREPARATION OF MEIOSIS-REGULATING MEDICAMENTS AND METHOD FOR THE PREPARATION THEREOF

#### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

#### Timing and Fees

<ul> <li>Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:         <ul> <li>within three months of the filing date of a national application other than a CPA under § 1.53(d);</li> <li>within three months of the actual filing date of the national phase of a PCT application; OR</li> <li>before the mailing of a first substantive office action (including after filing of an RCE).</li> </ul> </li> <li>Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:         <ul> <li>a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and</li> </ul> </li> </ul>							
under § 1.53(d);	$\boxtimes$						
application; OR  before the mailing of a first substantive office action (including after filing of an RCE).  Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:  a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR							
RCE).  Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:  a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR		<b>⊠</b> .					
specified in 37 C.F.R. § 1.97(b), but before the mailing date of:  a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `				
termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR							
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR				

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a	notice of allowance under 37 C.F.R. § 1.311;
	AND i	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents Ui	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	<u>Materia</u>	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		_	s of materials listed but not attached were cited in an international search dated October 13, 2004.
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-English	Language References
$\boxtimes$	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the</li> </ul>
	invention  E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date  D = cited in the application  L = cited for another reason  publication of member of same patent family
	Translation of other relevant information on foreign search report  [insert necessary translation here]
Other Inform	nation
	Fees Due (If Any):  eck for \$ covering the fee identified above is attached.
Pleas	se charge to Deposit Account No. 13-3402 \$ for the fee identified above.

10/566282

## IAP20 Residente to 30 JAN 2006

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. 27,969 Attorney for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1976

Date: January 30, 2006

AJZ:apl

K:\Sch\1976\Information Disclosure Statement.doc



Please type a plus sign (+) inside this box	+
---	---

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PT(	)		Complete if Known		
				Application Number	Unassigned 1 2 0 1 2 0	
INFO	RMATION	DISC	LOSURE	Filing Date	January 30, 2006	
STAT	<b>EMENT B</b>	Y API	PLICANT	First Named Inventor	Thorsten BLUME et al.	
				Group Art Unit	Unassigned	
(	use as many sh	eets as ne	ecessary)	Examiner Name	Unassigned`	
Sheet	1	of	1	Attorney Docket Number	SCH-1976	

			U.S	S. PATENT DOCUMENTS			
Examiner Initials *	Cite No.1	U.S. Patent Document  Kind Code <sup>2</sup> Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY		
/KH/	1	2002188143			December 12, 2002		
/KH/	2	2846432		NYSTED LEONARD N	August 5, 1958		
/KH/	3	2813094		NYSTED LEONARD N	November 12, 1957		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Foreign Patent Docu Number⁴	Ment Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/KH/	4	EP	1245572		SCHERING AG	October 2, 2002		Equv to cite 1
/KH/	5	DE	1930473		SCHERING AG	December 17, 1970		
/KH/	6	wo	9945024		MARSDEN JOHN CHRISTOPHER	September 10, 1999		
					·			

Examiner Signature	/Kahsay Habte/	Date Considered	11/24/2008

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.